Think Research new buy rating DesjardinsLooks like there is a new Analyst covering HealthTech at Desjardins. Comments on THNK:
Think Research Corp. (THNK-X) with a “buy” rating and $2.25 target. Average: $3.08.
“With the deluge of new clinical knowledge available every year, we believe it is increasingly difficult for health professionals to keep up with the latest medical information,” he said. “Hence, we have no doubt that the adoption of integrated platforms has significant growth runway and that THNK is well-positioned to benefit from this trend with its SaaS-based offerings. We believe it is fair to wonder how a small company such as THNK can be a meaningful player with monetization potential in an industry in which IT behemoths participate and which is notoriously complex. That said, healthcare is an enormous category that has been lagging other sectors in terms of digital adoption and we believe that—sadly for fax enthusiasts—COVID-19 was an inflection point for healthcare organizations’ willingness to adopt new ways of working. We also believe that management can leverage THNK’s small size to rapidly adapt to new industry trends. Other industry challenges that we believe THNK can help address include (1) the growing desire for convenience and enhanced technology solutions by younger generations—including physicians and healthcare practitioners, and (2) the burdened healthcare system which is in need of finding efficiencies.”